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ABSTRACT 
Objectives: This study was carried to evaluate and compare the physicochemical parameters and cost of available brands of amlodipine besylate 5 
mg marketed in Southern Nigeria. 
Methods: Fifteen brands were subjected to weight uniformity, friability, hardness, disintegration time, dissolution and chemical content tests. The 
chemical content test was performed using RP-HPLC method with isocratic run using acetonitrile: acetone buffer (50:50) as mobile phase at a flow 
rate of 0.8 ml/min and 237 nm wavelength of detection.  
Results: All the brands tested passed the weight uniformity test with no significant difference in values within each brand at p<0.05. The crushing 
strength values of only five brands were within official specification. All the brands passed the disintegration time and friability tests while only ten 
brands passed the content assay. The dissolution test revealed that all the brands released 70 % of their drug content within 45 min. The shelf price of 
the innovator product was N8, 500 (USD 43) for a pack of 100 tablets while the other products were about N3,000 (USD 15) for an equivalent pack. 
Conclusion: It can be concluded that though all the brands tested showed good dissolution profiles, only ten brands could be regarded as 
pharmaceutical equivalents according to their content assay and the price disparity between the products studied cannot be justified by the 
outcome of this physicochemical evaluation. 
Keywords: Amlodipine, 5 mg, Multisource products, Physicochemical evaluation, RP-HPLC. 
 
INTRODUCTION 
The goal of antihypertensive therapy is to abolish the risks 
associated with blood pressure elevation without adversely affecting 
quality of life. Drug selection is based on efficacy in lowering blood 
pressure and in reducing cardiovascular end points including stroke, 
myocardial infarction and heart failure [1]. Amlodipine is well 
tolerated by majority of patients with very limited side effects. Its 
prolonged half-life (t1/2
Medication cost is a chief determinant of the affordability and 
adherence to any treatment regimen. The high cost of branded 
products has encouraged the influx of generics (unbranded drug 
products) into Nigeria which are cheaper and are expected to be bio-
equivalent to the branded. The essential drug concept supports the 
use of generic medicines so as to improve access to essential 
medicines via drug price control. A generic medicine is defined as an 
exact simulation of an established drug product (called the branded 
product), not protected by a patent and promoted with the chemical 
name of the active ingredient [4].  
) of 35-50 h when administered at a dose of 
10 mg daily offers maximum convenience to the patient [2].  
The influx of so many generic products into the country has led to 
reports of substandard and counterfeit drugs which are often less 
expensive in order to attract higher market patronage [5]. Also the 
emergence of newer generics in the market and the disappearance 
of older ones have created some alarming fears and worries on the 
minds of the patients (the end users) and stakeholders over the 
years. Quality control tests are important tools that can be used in 
assessing the genuineness of drug products before their 
consideration for possible substitution and/or inter changeability of 
different multi-source brands of a drug [6]. 
For instance, a study was carried out in 2011 that evaluated ten 
brands of amlodipine tablets sourced from some southern states of 
Nigeria [7]. A similar study carried out two years later identified 
three new products in circulation in the same region [8]. The need to 
continuously assess the equivalence of clinically useful 
pharmaceutical multi brands and generics cannot be over 
emphasized. 
HPLC is considered the best technique for developing precise, accurate, 
linear, robust, stable and rugged analytical methods in pharmaceutical 
dosage forms [9]. Speed and accuracy are the most crucial aspects in 
quality control laboratories and HPLC analyses afford both advantages. 
European Pharmacopoeia describes assay of amlodipine besylate by 
reversed phase high performance liquid chromatography in bulk and 
pharmaceutical formulations. Amlodipine besylate behaviour and 
quality had been studied extensively by methods such as 
spectrophotometric [10], voltametric [11] and chromatographic (12]. 
This study is geared towards ascertaining the credibility of the labelled 
claims of the available brands of amlodipine besylate sold in ten 
southern states of Nigeria. It is also designed to determine whether the 
price differences between these numerous generics of amlodipine in the 
market are a reflection of the quality of the products. 
MATERIALS AND METHODS 
The samples (table 1) studied were purchased from pharmacies across 
ten southern States in Nigeria (namely: Lagos, Ondo, Edo, Delta, 
Anambra, Enugu, Imo, Ebonyi, Rivers and Akwa-Ibom). Available 
brands in each state were selected to make up the fifteen brands 
studied. Brands already selected from one state were no longer 
considered in any other state. Pure amlodipine powder was gratefully 
received from Juhel Nigeria Limited, Enugu State, Nigeria. All other 
reagents were of analytical grade and water was double distilled. 
Weight uniformity 
The weight of each of 20 tablets was determined from each brand using 
an electronic balance (College B154, Mettler Toledo, Switzerland) and 
the mean weight and standard deviation were computed. 
Hardness  
The crushing strength of ten tablets per brand was determined by 
diametric compression of each tablet (Campbell Electronics, Model 
HT-30/50, India). The mean value was calculated. 
Friability 
Ten previously weighed tablets per brand were placed in the drum 
of a friabilator (Erweka GmbH, Germany) revolving at 25 rpm. After 
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4 min, the tablets were brought out, dedusted and reweighed. 
Friability was calculated as the percentage loss in weight. 
Disintegration time 
The disintegration times of six tablets per brand were determined in 
distilled water at 37±0.5 °C using the BP disintegration tester (MK 
IV, Manesty Machines, UK). 
Content of active drug 
Chromatographic conditions 
Chromatographic separation was performed on an Agilent 1200 
Infinity Series (Agilent Technologies Inc., USA) arranged with a 
gradient pump, rheodyne injector, column oven and VWD detector. 
An Agilent ZORBAX XDB, 150 mm x 4.6 mm, 5-µ column was used as 
the stationary phase. Drug samples were separated isocratically with 
a mobile phase consisting of acetonitrile and 0.025 M potassium 
dihydrogen phosphate buffer adjusted to pH of 4.0±0.1 (60:40) at a 
flow rate of 0.8 ml/min. The analysis was carried out at 30 °C and 
the injection volume was 10 µl. The detector was set at 237 nm. 
Mobile phase preparation 
Potassium dihydrogen phosphate salt (4 g) was weighed into a 1 L 
beaker and dissolved with sufficient distilled water. Triethylamine 
(0.5 ml) was added and the pH was adjusted to 4.0 with ortho-
phosphoric acid. The volume was then adjusted to 1 L. Four hundred 
millilitres of the solution was transferred into a beaker and 600 ml 
of HPLC grade acetonitrile was added to it. The premix mobile phase 
was filtered through a 0.45 µm nylon filter with the aid of a vacuum 
pump and then used in equilibrating the HPLC column and system. 
Standard calibration curve 
The standard solution of amlodipine was prepared by weighing 
amlodipine besylate working standard equivalent to 5 mg and 
diluting with 10 ml of methanol-distilled water mixture (50:50). 
From the stock solution, serial dilutions were made to obtain 
solutions of concentrations ranging from 5-100 µg/ml. Six injections 
of the final solutions were run on the HPLC system to determine 
system suitability and also calibrated to quantify the samples. The 
mean peak area (mPA) of the determinations for each concentration 
was plotted against the respective concentration to get the 
calibration curve. 
Sample preparation 
Twenty tablets of each brand were weighed and pulverized into 
powder. A quantity of the powder equivalent to 5 mg of amlodipine 
besylate was weighed into a 100 ml volumetric flask and dissolved 
with about 70 ml of the diluent (methanol: distilled water). The sample 
was sonicated for about 10 min and then made up to 100 ml with 
sufficient diluent. A 1 ml aliquot of the solution was further diluted to 
100 ml and filtered before injection into the chromatographic system 
[13]. Three injections were run on each brand and the average peak 
area for the triplicate measurement was extrapolated on the 
calibration curve derived from the pure amlodipine powder to obtain 
the equivalent concentration and the percentage content calculated 
[14]. The mobile phase was also run as the blank. 
Dissolution studies 
Various amlodipine standard concentrations ranging from 1.0-25 
μg/ml were prepared from stock solutions with 0.1M HCl and 
subjected to ultra-violet spectrophotometric analysis at 237 nm 
(T70, PG Instruments Ltd, USA). Respective absorbances were taken 
and lines of regression were determined. The calibrator prepared 
was used for the analysis of the dissolution samples. 
Dissolution tests were carried out using a BP dissolution test 
apparatus (Caleva ST7, GB Caleva. UK). This was fitted with a basket 
rotated at 100 rpm using 900 ml of 0.1M HCl (pH 1.15) solution as the 
dissolution medium maintained at 37±0.5 °C. Three tablets selected at 
random from each brand were used simultaneously for the study. A 5 
ml volume of dissolution fluid were withdrawn at various intervals 
and replaced with an equivalent volume maintained at the same 
temperature (37±0.5 °C). This was continued for 60 min. The sample 
was filtered and diluted with an equal volume of 0.1M HCl. The 
absorbances of the resulting solutions were measured at λmax of 237 
nm. The percentage of drug released was then calculated from the 
equation obtained from the calibration curve. 
Statistical analysis 
All the results obtained are expressed as mean±standard deviation 
and were subjected to the student t-test statistical analysis to test for 
significance of difference using Microsoft Excel 2007. p<0.05 was 
considered to be statistically significant.  
RESULTS AND DISCUSSION 
All the fifteen (15) brands of amlodipine used in the study were 
uncoated immediate release tablet dosage forms and were still 
within their shelf life as at the time of study. All except one were 
registered with National Agency for Food Drug Administration and 
Control (NAFDAC). The summary of the drug codes and details 
including the estimated prices in the region are presented in table 1. 
All the brands were packaged in photo-protective foil strips to 
prevent light degradation. When observed visually, all the brands 
showed similarities in colour as they were mostly white with a slight 
difference in size, shapes and inscriptions. 
The results of the weight uniformity test are shown in the table 2. All 
the brands complied with weight uniformity test specifications which 
stipulate that not more than two tablets should have maximum 
deviation from the mean weight of 5 % and none with a maximum 
deviation of 10 % [14]. This indicates that the individual doses are 
likely to be dependable and consistent with each repetitive intake. 
The results of the hardness test are shown in table 2. Adequate 
tablet hardness is essential to ensure resistance to damage during 
handling, packaging and transportation. Brands A2, A8 and A13 
were well within the acceptable limit of 5.0-8.0 kp [14] although 
crushing strength values as low as 4.0 kp is considered minimum for 
a satisfactory tablet [15].  
Brands A3, A9 and A10 were below the acceptable limit of hardness. 
This may account for the brittle nature of brand A3, as some of the 
tablets crumbled on being removed from their blister pack. Also, A1, 
A4-A7, A14 and A15 were above the acceptable limit. This may be 
attributed to excessive compression pressure during tableting or too 
much binder. Care should be taken by manufacturers not to 
formulate an overly hard tablet as it may adversely affect 
disintegration time and in turn disso lution. 
All the brands under investigation passed the friability test as shown 
in table 2. They exhibited friability values ranging from 0.03 % to 
0.69 % which is well below the stipulated maximum permissible 
value of 1 % loss of weight of the tablet tested [14]. This test also 
indicates the ability of the tablets to withstand wear during handling 
and transportation. This alongside hardness is an indication of 
appropriate choice of binder and compression pressure. 
All the brands disintegrated within 15 min (table 2). This is well 
within the acceptable limit for uncoated immediate release tablets. 
Brand A9 showed the least disintegration time of 5 sec while brand 
A7 showed the highest value of 548 seconds (9.13 min).  
The results of the chemical content assay are also shown in table 2. 
Only brands A1, A7 and A8 had chemical contents below the official 
specification of 95 % to 105 % as stipulated in BP, 2011 [16]. The 
innovator product (Br and A1) had a chemical content slightly below 
the official standard. This may be as a result of non-compliance with 
GMP, production negligence or drug instabilities. Amlodipine is 
known to be thermo-labile, therefore poor storage conditions 
probably employed by the intermediaries between the 
manufacturers and patients may have caused degradation which 
may account for the low chemical content observed in these brands. 
Products A2 and A6 showed high chemical content above the 
permitted official value. This may be due to production error. 
However, the fact that out of the fifteen brands assessed, only nine 
passed the content assay is worrisome. This is seriously implicated 
in numerous drug therapy failures observed in Nigeria today [17]. 
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Table 1: Selected brands of amlodipine besylate (5 mg) tablets used in the study 
Brand 
code 
















D10269031 04-1386 10×10 8500 Norvasc 
A2 Atlanta Pharma Sintral, Portugal 01/2014 
01/2016 
KA0045A A4-0908 10×3 1200 Lofral 
A3 Neimeth International 
Pharm. PLC, Nigeria 
02/2014 
02/2017 
40105100 A4-0332 10×10 4500 Amlovar 
A4 Baroque Pharmaceuticals Pvt Ltd, India 05/2013 
04/2016 
(10)B3021 A4-3433 10×3 450 Ambes 
A5 Zhejiang Pharmaceutical Co Ltd, China 05/2013 
04/2015 
130501 A4-4070 10×3 500 Cladipine 
A6 Macleods Pharmaceuticals Ltd, India 04/2013 
03/2016 
EAY301A A4-6991 10×3 350 Amland 
A7 Zhejiang Pharmaceutical Co Ltd, China 09/2013 
08/2016 
130903 A4-4131 10×3 500 Pemaload 
A8 Jiangsu Ruinian Qianjon Pharm. Co Ltd, China 07/2013 
07/2016 
130713 A4-7894 10×3 400 Rodivas 
A9 MA Holder Teva UK Ltd, UK 07/2014 
06/2019 
4G73UK - 14×2 400 Amlodipine 
A10 Maxheal Laboratories 
Pvt Ltd, India 
03/2013 
02/2016 
NP3003 A4-8407 10×3 750 Norapine 




015AS 04-3149 10×3 750 Amlovas 
A12 Strides Vital Nig. Ltd, Ikeja, Nigeria 08/2013 
07/2016 
5640281 A4-4593 10×10 1800 Amloster 
A13 Mercury Laboratories 
Pvt Ltd, India 
08/2014 
07/2017 
14160002 A4-1664 10×3 600 Amlocard 









AMGH0014 A4-0441 10×3 400 Amlong 
 















Content of amlodipine (%) 
(N=20) 
A1 200.72±1.18 10.25±0.77 0.14±0.22 14±1.50 94.92±1.50 
A2 200.36±1.57 5.10±0.39 0.09±0.16 6.0±0.20 115.48±1.20 
A3 201.41±3.10 2.68±0.26 0.69±0.06 9.0±0.40 98.69±1.21 
A4 252.08±3.71 10.25±1.19 0.27±0.02 17±0.40 96.01±4.70 
A5 154.37±2.31 10.65±0.93 0.04±0.42 290±2.32 100.15±5.21 
A6 134.69±0.65 8.47±1.30 0.56±0.50 16±1.18 113.18±4.96 
A7 155.92±3.04 11.42±0.50 0.40±0.62 548±5.50 91.85±6.17 
A8 234.76±2.27 4.65±1.12 0.22±0.40 113±3.10 93.37±4.50 
A9 202.08±1.80 3.50±1.46 0.04±0.34 5.0±1.06 100.13±1.45 
A10 171.81±2.52 2.95±0.47 0.22±0.12 76±0.35 101.32±2.54 
A11 307.37±4.28 6.28±1.92 0.22±0.40 60±0.60 97.74±1.55 
A12 190.89±3.73 4.63±1.18 0.21±0.10 30±1.26 99.35±4.58 
A13 163.50±4.61 7.35±0.67 0.24±0.20 258±3.45 95.77±4.65 
A14 184.38±3.67 9.38±0.43 0.03±0.18 130±3.10 98.83±2.35 
A15 191.19±1.70 8.50±0.89 0.17±0.24 11±1.60 103.37±1.50 
Values are mean±standard deviation 
 
Fig. 1a: Dissolution profiles of bands A1 (), A2 (), A3 (), A4 (), A5 (), A6 (), A7 () and A8 (). Data are expressed as the 
mean±SD (n= 3) 
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The dissolution profile plots for all the brands are shown in fig. 1a 
and b. All the brands showed satisfactory dissolution profiles. The 
BP, 2011 states that 70 % of the drug in uncoated tablet should 
dissolve within 45 min [16]. All the fifteen brands released more 
than 70 % of their contents in less than 45 min as shown in fig. 1a 
and b. This indicates that sufficient amount of the drug would be 
available for absorption to elicit the expected therapeutic effect 
when administered. Also, there is no significant difference (p<0.05) 
in the dissolution rates of all the brands assessed. Although 
comparative bioavailability studies would be required to draw 
clinical conclusions, the similarities obtained from the dissolution 




Fig. 1b: Dissolution profiles of bands A9 (), A10 (), A11 (), 
A12 (), A13 (), A14 () and A15 (). Data are expressed as 
the mean±SD (n= 3) 
 
The prices of the brands were generally below N1,000 for a pack of 
30 tablets which will amount to about N3,000 for a 100 tablets as 
against the innovator product sold for N 8,500. The innovator 
product was expected to be superior in the physicochemical and in 
vitro tests to warrant the price disparity. There was however no 
significant difference in the parameters tested. The wide disparity in 
price between the innovator product and the generics cannot be 
justified based on the results obtained from this study. 
CONCLUSION 
The failure of some of the brands tested to meet up with the labelled 
claim of chemical content as well as significant differences in physical 
parameters will require a re-evaluation on the part of the 
manufacturers/importers and regulating authorities to avoid allowing 
substandard drug products in the market. Innovator products will 
need to be stored and handled properly for it to continue to deliver the 
expected standard of actions for this may have accounted for the 
observed drop in the labelled claim of sample A1. The similar release 
profile observed among the brands may warrant inter-changeability 
between the brands which may not alter bioavailability significantly. 
The high expectation of quality action placed on the branded product 
resulting in high pricing may not be justified after all. 
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